Kiniksa Pharmaceuticals International PLC
KNSA40.665USD
+1.165+2.95%
交易中 （美東）報價延遲15分鐘
3.07B總市值
85.39本益比TTM
關於 Kiniksa Pharmaceuticals International PLC 公司
Kiniksa Pharmaceuticals International, plc 是一家商業階段的生物製藥公司，專注於發現、收購、開發和商業化治療藥物，用於治療患有嚴重衰弱性疾病且醫療需求未得到滿足的患者。其免疫調節資產組合 ARCALYST、abiprubart 和 mavrilimumab 基於強大的生物學原理或經過驗證的機制，針對一系列醫療資源不足的心血管和自身免疫疾病，並具有差異化潛力。ARCALYST 是一種白細胞介素-1α 和白細胞介素-1β 細胞因子誘捕器。ARCALYST 用於治療複發性心包炎並降低成人和 12 歲及以上兒童的復發風險。 ARCALYST 還被批准用於治療冷吡啉相關週期性綜合徵 (CAPS)，包括家族性冷自身炎症綜合徵 (FCAS) 和 Muckle-Wells 綜合徵，以及維持白細胞介素-1受體拮抗劑缺乏症的緩解。
Kiniksa Pharmaceuticals International PLC簡介
公司代碼KNSA
公司名稱Kiniksa Pharmaceuticals International PLC
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
員工數量315
證券類型Ordinary Share
年結日May 24
公司地址23 Old Bond Street, Floor 3
城市LONDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編WIS 4PZ
電話
網址https://www.kiniksa.com/
公司代碼KNSA
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
Kiniksa Pharmaceuticals International PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
28.68K
-16.98%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
28.68K
-16.98%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
暫無數據
地區USD
名稱
營收
佔比
United States
156.51M
99.81%
United Kingdom
291.00K
0.19%
Rest oF World
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 10月17日 週五
更新時間: 10月17日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Rubric Capital Management LP
8.66%
The Vanguard Group, Inc.
6.77%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
其他
69.24%
持股股東
持股股東
佔比
Rubric Capital Management LP
8.66%
The Vanguard Group, Inc.
6.77%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
其他
69.24%
股東類型
持股股東
佔比
Hedge Fund
42.72%
Investment Advisor/Hedge Fund
24.18%
Investment Advisor
18.18%
Research Firm
4.48%
Individual Investor
3.61%
Pension Fund
0.47%
Bank and Trust
0.18%
Family Office
0.10%
Corporation
0.02%
其他
6.07%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
419
40.93M
90.64%
-3.92M
2025Q2
396
42.64M
98.10%
-1.50M
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Rubric Capital Management LP
3.91M
8.99%
+526.57K
+15.56%
Jun 30, 2025
The Vanguard Group, Inc.
3.12M
7.19%
-225.66K
-6.74%
Jun 30, 2025
Baker Bros. Advisors LP
2.82M
6.5%
+6.35K
+0.23%
Jun 30, 2025
Tang Capital Management, LLC
2.33M
5.36%
+210.03K
+9.91%
Jun 30, 2025
Fairmount Funds Management LLC
1.77M
4.08%
+670.59K
+60.84%
Jun 30, 2025
Acadian Asset Management LLC
1.27M
2.92%
+233.67K
+22.59%
Jun 30, 2025
Braidwell LP
1.10M
2.54%
-860.33K
-43.83%
Jun 30, 2025
Desnick (Robert)
1.05M
2.42%
--
--
Apr 08, 2025
Millennium Management LLC
1.02M
2.35%
+172.84K
+20.40%
Jun 30, 2025
Pictet Asset Management Ltd.
984.60K
2.26%
-149.33K
-13.17%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
2.33%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.23%
WisdomTree US SmallCap Fund
0.19%
Fidelity Enhanced Small Cap ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
Fidelity MSCI Health Care Index ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Virtus LifeSci Biotech Products ETF
佔比2.33%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.23%
WisdomTree US SmallCap Fund
佔比0.19%
Fidelity Enhanced Small Cap ETF
佔比0.12%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.04%
Fidelity MSCI Health Care Index ETF
佔比0.02%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
